Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.76 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599138 | 0.86 | HCAR3 (1.00) | HCAR3HPGDHCAR2MEN1RAB9A | |
| SCHEMBL12349868 | 0.86 | HCAR3 (0.57) | HCAR3HPGDMEN1RAB9AKMT2A | |
| SCHEMBL29751355 | 0.85 | HCAR3 (0.55) | HCAR3HPGDMEN1RAB9AKMT2A | |
| SCHEMBL2884485 | 0.82 | HCAR3 (0.53) | HCAR3HPGDMEN1RAB9AKMT2A | |
| SCHEMBL2852713 | 0.81 | HSD17B10 (0.56) | HCAR3HPGDHCAR2POLB | |
| SCHEMBL6184550 | 0.80 | HCAR3 (0.80) | HCAR3HPGDHCAR2 | |
| SCHEMBL8712864 | 0.80 | NPC1 (0.55) | HCAR3HPGDMEN1RAB9AKMT2A | |
| SCHEMBL7232454 | 0.79 | HCAR3 (0.53) | HCAR3HPGDHCAR2KMT2A | |
| SCHEMBL6182902 | 0.79 | HCAR3 (0.78) | HCAR3HPGDHCAR2MEN1RAB9A | |
| SCHEMBL11391092 | 0.79 | HCAR3 (0.53) | HCAR3HPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4271672-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4204411-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022225941-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022046861-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| CN-1681805-A | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER PROD INC (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542990-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004026859-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | disclosed |
| WO-1992022536-A1 | VINYLIMIDAZOLES, VINYLTRIAZOLES AND VINYLTETRAZOLES WITH A BICYCLIC SUBSTITUENT GROUP | SCHERING AKTIENGESELLSCHAFT, BERLIN UND BERGKAMEN (DE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518457-A1 | Bicyclic substituted vinylimidazoles, -triazoles and -tetrazoles | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-16 | — | — | EP | disclosed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | HCAR3 4732/4885HPGD 3097/4885HCAR2 4842/4885 |
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, TGFBR2 | HCAR3 2875/4885HPGD 973/4885HCAR2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.